Remitting

Diabetes drug shows promise against multiple sclerosis

...etes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago Co...ogy . In a small, double-blinded clinical trial, patients with relapsing remitting multiple sclerosis were assigned to take pioglitazone (a drug commercially ...

Hookworms in MS trial

... is led by Professor Cris Constantinescu and Professor David Pritchard and is a randomised, placebo controlled, phase 2 study in people with relapsing remitting MS and will be carried out at multiple centres up and down the country. The 25 worms are microscopic and are introduced painlessly through a patch ...

Simple, inexpensive and objective tools for the assessment of mucosal inflammation: fecal markers

... UC and CD, the two major forms of IBD are chronic, idiopathic inflammatory conditions of the gut with a typically relapsing and remitting course. A prominent feature in mucosal biopsies from patients with active IBD is infiltration by neutrophil granulocytes. Moreover, the number of eosi...

Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center

...el Disease, split roughly evenly between the two manifestations of the disease: Crohn's disease (CD) and ulcerative colitis (UC). IBD is a relapsing / remitting chronic disease with gastrointestinal symptoms such as diarrhoea, rectal bleeding and abdominal pain. The study is led by a leading Israeli Gast...

Prozac Reduces Disease Activity in MS Patients

...inds antidepressant cut inflammation in relapsing remitting illness WEDNESDAY, April 30 (HealthDay...duce disease activity in people with the relapsing remitting form of multiple sclerosis (MS), a new study sugge...t the use of fluoxetine in patients with relapsing remitting MS can be made, the study authors noted. Howeve...

Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS

... trial in untreated patients with relapsing-remitting multiple sclerosis. -- Two-year Results with Alemtuzumab in Patients with Active Relapsing- remitting Multiple Sclerosis Who Have Failed Licensed Beta-Interferon Therapies. Saturday, October 13 from 3:30-5:00 p.m. Ed Fox, M.D. In another post...

Citalopram, a Boon in Treating Depressed Heart Patients

...in depression. Standardized depression scores were 67 percent more likely to drop by half on citalopram than placebo, and the chance of depression remitting was almost doubled. Says Dr. Lesperance, "Citalopram or sertraline, as previously shown in [a different trial], plus clinical management should b...

Help at hand for RRMS patients

...l injury and induced neuronal metabolic recovery in patients with relapsing remitting multiple sclerosis (RRMS). // COPAXONE? (glatiramer acetate injection...E? is indicated for the reduction of the frequency of relapses in relapsing remitting multiple sclerosis. The most common side effects of COPAXONE? are redness, ...

Remitting in Medical Technology

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

... of Neurology, Cologne City Hospitals, Germany. As previously reported, ATL/TV1102 significantly reduced disease activity in patients with Relapsing remitting Multiple Sclerosis (RRMS) in a randomized, double-blind, placebo-controlled Phase II study designed to obtain evidence of ATL/TV1102's effectiveness i...

Genmab Announces Upcoming Ofatumumab Studies

... developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country. ...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

...ishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009. "This patent represents an important component in the development of our intellectual property in peptide...

Genmab Reaches Milestone in Ofatumumab Collaboration

...mately USD 6 million) was triggered by treatment of the first patient participating in the Phase II study of ofatumumab for the treatment of relapsing remitting multiple sclerosis (RRMS). "Our collaboration with GSK continues to progress as both companies work towards providing new treatment options for pati...

Isis Pharmaceuticals Conference Call Notice

... to view the release titled: Teva Pharmaceuticals & Antisense Therapeutics Announce That ATL/TV 1102, a Novel Drug for the Treatment of Relapsing remitting Multiple Sclerosis Demonstrated Significant Reduction in Disease Activity To access this call via telephone Please call 1-877-548-7901 in the Un...

Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings

...ioavailability and pharmacodynamic effects with PI-2301, provide further evidence that PI-2301 may replace Copaxone as first-line therapy in relapsing remitting multiple sclerosis," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301 to maximize the therapeutic benefit of a pro...

Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis

...tium of centers involved in studying new therapies for the treatment for multiple sclerosis. This study will enroll patients with aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). Mitoxantrone, a related compound which is less active in preclinical studies, has been app...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

...cumulation of disability in early active relapsing remitting multiple sclerosis (RRMS) patients compared to Reb...ypically characterized by an initial relapsing and remitting phase where episodes of transient neurological com...itive and visual impairments. At onset, relapsing- remitting MS is the most common form of this disease. Abou...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

..., Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with Relapsing remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on MRI Markers of Disease Burden and Black Hole Evolution, evaluated whether effects on ...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

..., Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with Relapsing remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on MRI Markers of Disease Burden and Black Hole Evolution, evaluated whether effects on ...

More>>

Remitting in Biological News

MS study offers theory for why repair of brain's wiring fails

... oligodendrocytes to the myelin sheath to repair the damage, for a time. This explains why, in the most common form of the disease, known as relapsing remitting MS, the symptoms -- which range from tingling and numbness in the limbs to loss of vision and paralysis -- disappear or are greatly reduced, for some ...

Remitting in Biological Technology

BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis

Toronto Stock Exchange Symbol: MS EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with r...

BioMS Medical recognized at Scrip Awards 2008

...condary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://biomsmedical.com ...

Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance

...secondary progressive MS, one in Europe and Canada, and the other in the U.S. There is also a Phase II clinical trial underway in Europe for relapsing remitting MS. -- Tasisulam (ASAP) - Currently in Phase II, tasisulam has exhibited properties resembling a targeted agent as well as a cytotoxic. The co...

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

... developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any c...

BioMS Medical Announces Third Quarter 2008 Results

...condary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli...

BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference

...condary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli...

Peptimmune Presentations at Upcoming Events

...ishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009. PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharm...

Genmab Reaches Milestone in Ofatumumab Collaboration

... developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co- development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any ...

BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board

...condary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli...

BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board

...condary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli...